<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="inhibitor that has previously demonstrated efficacy in the treatment of" exact="influenza" post="in adults and adolescents. We assessed the safety and"/>
 <result pre="(95% confidence interval) to alleviation of signs and symptoms of" exact="influenza" post="was similar between groups: 138.1 (116.6â€&quot;163.2) hours with baloxavir"/>
 <result pre="therapeutic option with a simple oral dosing regimen. baloxavir marboxil" exact="influenza" post="children oseltamivir virology Annual influenza epidemics are estimated to"/>
 <result pre="oral dosing regimen. baloxavir marboxil influenza children oseltamivir virology Annual" exact="influenza" post="epidemics are estimated to cause 3â€&quot;5 million cases of"/>
 <result pre="deaths annually.7 In addition, children play a central role in" exact="influenza" post="dissemination in the community because of their relative susceptibility"/>
 <result pre="is the most effective control measure for prevention of seasonal" exact="influenza" post="and related complications.9,10 Vaccination is recommended in the United"/>
 <result pre="only 2 classes of antivirals approved for the treatment of" exact="influenza" post="in children: M2 blockers and neuraminidase inhibitors.3 Widespread, stable"/>
 <result pre="ineffective.14,15 Although neuraminidase inhibitors are effective in the treatment of" exact="influenza" post="in children, there are restrictions for some of these"/>
 <result pre="safety and tolerability, is considered desirable for the treatment of" exact="influenza" post="in children. Baloxavir marboxil (baloxavir) is a novel, first-in-class,"/>
 <result pre="the initial indication included single-dose, oral treatment of acute uncomplicated" exact="influenza" post="in patients â‰¥12 years old, who have been symptomatic"/>
 <result pre="studies, baloxavir showed significant improvements in time to alleviation of" exact="influenza" post="symptoms (CAPSTONE 1) and time to improvement of influenza"/>
 <result pre="of influenza symptoms (CAPSTONE 1) and time to improvement of" exact="influenza" post="symptoms (CAPSTONE 2) compared with placebo, and faster reduction"/>
 <result pre="treatment in otherwise healthy children 1â€&quot;&amp;lt;12 years old with acute" exact="influenza" post="from miniSTONE-2 (Clinicaltrials.gov identifier: NCT03629184), a phase III, randomized,"/>
 <result pre="influenza. The trial enrolled children 1â€&quot;&amp;lt;12 years of age with" exact="influenza" post="(who were otherwise healthy) during the 2018/2019 Northern Hemisphere"/>
 <result pre="influenza (who were otherwise healthy) during the 2018/2019 Northern Hemisphere" exact="influenza" post="season, including sites in the United States, South America"/>
 <result pre="America and Europe. Enrolled children had a clinical diagnosis of" exact="influenza" post="infection consisting of fever (tympanic temperature of â‰¥38Â°C) at"/>
 <result pre="screening was â‰¤48 hours. The trial excluded children with severe" exact="influenza" post="symptoms requiring inpatient treatment and those with concurrent infections"/>
 <result pre="hepatitis, cirrhosis, or pulmonary disease, known chronic renal failure, active" exact="cancer" post="at any site, or a history of organ transplantation."/>
 <result pre="including time to alleviation of signs and symptoms (TTASS) of" exact="influenza" post="[defined as when a score of 0 (no problem)"/>
 <result pre="predefined and required investigator confirmation: death, hospitalization, pneumonia, bronchitis, sinusitis," exact="otitis media," post="encephalitis/encephalopathy, febrile seizures or myositis) and proportion of children"/>
 <result pre="viral shedding by virus titer and change from baseline in" exact="influenza" post="virus titer.23 Exploratory virologic endpoints included frequency of treatment-emergent"/>
 <result pre="who had a laboratory reverse transcriptase-polymerase chain reaction confirmation of" exact="influenza" post="infection from any swab sample collected at baseline or"/>
 <result pre="169 children (96%) completed the trial (Fig. 1). The predominant" exact="influenza" post="A subtype at baseline assessed by reverse transcriptase-polymerase chain"/>
 <result pre="for both groups, followed by H1N1pdm09. Numbers were low for" exact="influenza" post="B in both groups (n = 5 for baloxavir"/>
 <result pre="had a laboratory reverse transcriptase polymerase chain reaction confirmation of" exact="influenza" post="infection from any swab sample collected at baseline or"/>
 <result pre="group, including accidental overdose of oseltamivir placebo and grade 2" exact="rash" post="occurring on day 4 that resolved after 24 hours"/>
 <result pre="baloxavir than oseltamivir; Table 3). The number of children with" exact="influenza" post="B was too low to allow meaningful interpretation of"/>
 <result pre="who had a laboratory reverse transcriptase-polymerase chain reaction confirmation of" exact="influenza" post="infection from any swab sample collected at baseline or"/>
 <result pre="(7.0%) in the oseltamivir group. The most frequent complication was" exact="otitis media" post="in both groups [3 (2.6%) for baloxavir, 4 (6.9%)"/>
 <result pre="baloxavir, 4 (6.9%) for oseltamivir], with single cases of bronchitis," exact="pneumonia" post="and sinusitis (baloxavir) and febrile seizure (oseltamivir). The proportion"/>
 <result pre="(6.9%) for oseltamivir], with single cases of bronchitis, pneumonia and" exact="sinusitis" post="(baloxavir) and febrile seizure (oseltamivir). The proportion of children"/>
 <result pre="both groups: 2 children in each group received antibiotics for" exact="otitis media" post="and 2 children in the baloxavir group received antibiotics"/>
 <result pre="and 2 children in the baloxavir group received antibiotics for" exact="pneumonia" post="and sinusitis. Secondary Objective: Virology As previously observed in"/>
 <result pre="titer compared with oseltamivir. The mean reduction from baseline in" exact="influenza" post="virus titer on day 2 (24 hours posttreatment) was"/>
 <result pre="were detected in 11 of 57 children (19.3%); 9 had" exact="influenza" post="A subtype H3N2 and 2 had subtype H1N1pdm09. However,"/>
 <result pre="formation of new virions by blocking replication early in the" exact="influenza" post="life cycle.16,17 Two previous Japanese studies evaluating the use"/>
 <result pre="Most AEs were considered by investigators to be related to" exact="influenza" post="infection. In both treatment groups, most AEs were either"/>
 <result pre="inhibitor, baloxavir can offer benefit in patients hospitalized with severe" exact="influenza" post="(Clinicaltrial.gov identifier: NCT03684044). Multiple viral infections are frequent in"/>
 <result pre="no bacterial coinfections at baseline, and only 3 cases of" exact="otitis media" post="(2 requiring antibiotics) observed in the baloxavir arm following"/>
 <result pre="therefore, these results may potentially indicate a reduction in acute" exact="otitis media" post="complications following baloxavir treatment, compared with the 1 in"/>
 <result pre="absence of a specific analysis of the reduction in acute" exact="otitis media" post="complications following baloxavir treatment. All influenza antivirals can lead"/>
 <result pre="reduction in acute otitis media complications following baloxavir treatment. All" exact="influenza" post="antivirals can lead to the emergence of resistant variants"/>
 <result pre="single oral dose of baloxavir is well-tolerated, effective at alleviating" exact="influenza" post="signs and symptoms, and results in rapid elimination of"/>
 <result pre="North Am. 2017;64:911â€&quot;936.28734518 3.PaulesCSubbaraoKInfluenza.Lancet. 2017;390:697â€&quot;708.28302313 4.MorrisDEClearyDWClarkeSCSecondary bacterial infections associated with" exact="influenza" post="pandemics.Front Microbiol. 2017;8:1041.28690590 5.CastrucciMRFactors affecting immune responses to the"/>
 <result pre="influenza pandemics.Front Microbiol. 2017;8:1041.28690590 5.CastrucciMRFactors affecting immune responses to the" exact="influenza" post="vaccine.Hum Vaccin Immunother. 2018;14:637â€&quot;646.28617077 6.RufBRKnufMThe burden of seasonal and"/>
 <result pre="vaccine.Hum Vaccin Immunother. 2018;14:637â€&quot;646.28617077 6.RufBRKnufMThe burden of seasonal and pandemic" exact="influenza" post="in infants and children.Eur J Pediatr. 2014;173:265â€&quot;276.23661234 7.IulianoADRoguskiKMChangHHet al.collab:"/>
 <result pre="respiratory mortality: a modelling study.Lancet. 2018;391:1285â€&quot;1300.29248255 8.ViboudCBoÃ«llePYCauchemezSet al.Risk factors of" exact="influenza" post="transmission in households.Br J Gen Pract. 2004;54:684â€&quot;689.15353055 9.NicholKLTreanorJJVaccines for"/>
 <result pre="Advisory Committee. Strategies to achieve the healthy people 2020 annual" exact="influenza" post="vaccine coverage goal for health-care personnel: recommendations from The"/>
 <result pre="challenges and solutions.Cell Host Microbe. 2015;17:295â€&quot;300.25766291 12.LeeYTKimKHKoEJet al.New vaccines against" exact="influenza" post="virus.Clin Exp Vaccine Res. 2014;3:12â€&quot;28.24427759 13.HannounCThe evolving history of"/>
 <result pre="influenza virus.Clin Exp Vaccine Res. 2014;3:12â€&quot;28.24427759 13.HannounCThe evolving history of" exact="influenza" post="viruses and influenza vaccines.Expert Rev Vaccines. 2013;12:1085â€&quot;1094.24024871 14.BrightRAMedinaMJXuXet al.Incidence"/>
 <result pre="Vaccine Res. 2014;3:12â€&quot;28.24427759 13.HannounCThe evolving history of influenza viruses and" exact="influenza" post="vaccines.Expert Rev Vaccines. 2013;12:1085â€&quot;1094.24024871 14.BrightRAMedinaMJXuXet al.Incidence of adamantane resistance"/>
 <result pre="vaccines.Expert Rev Vaccines. 2013;12:1085â€&quot;1094.24024871 14.BrightRAMedinaMJXuXet al.Incidence of adamantane resistance among" exact="influenza" post="A (H3N2) viruses isolated worldwide from 1994 to 2005:"/>
 <result pre="15.NelsonMISimonsenLViboudCet al.The origin and global emergence of adamantane resistant A/H3N2" exact="influenza" post="viruses.Virology. 2009;388:270â€&quot;278.19394063 16.FukaoKAndoYNoshiTet al.Baloxavir marboxil, a novel cap-dependent endonuclease"/>
 <result pre="16.FukaoKAndoYNoshiTet al.Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses" exact="influenza" post="virus replication and represents therapeutic effects in both immunocompetent"/>
 <result pre="of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the" exact="influenza" post="virus polymerase PA subunit.Antiviral Res. 2018;160:109â€&quot;117.30316915 19.HaydenFGSugayaNHirotsuNet al.collab: Baloxavir"/>
 <result pre="19.HaydenFGSugayaNHirotsuNet al.collab: Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated" exact="influenza" post="in adults and adolescents.N Engl J Med. 2018;379:913â€&quot;923.30184455 20.IsonMGPortsmouthSYoshidaYet"/>
 <result pre="2018;379:913â€&quot;923.30184455 20.IsonMGPortsmouthSYoshidaYet al.Phase 3 trial of baloxavir marboxil in high-risk" exact="influenza" post="patients (CAPSTONE-2 study).Open Forum Infect Dis. 2018;5:S764â€&quot;S765. 21.collab: F."/>
 <result pre="respiratory infections.J Clin Epidemiol. 2000;53:793â€&quot;799.10942861 23.van BaalenCAElsCSprongLet al.Detection of nonhemagglutinating" exact="influenza" post="a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza"/>
 <result pre="nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative" exact="influenza" post="virus culture.J Clin Microbiol. 2014;52:1672â€&quot;1677.24622097 24.HirotsuNSakaguchiHSatoCet al.Baloxavir marboxil in"/>
 <result pre="in nasopharyngeal swab samples.J Clin Micobiol. 2018;56:e01945-17. 26.OmotoSSperanziniVHashimotoTet al.Characterization of" exact="influenza" post="virus variants induced by treatment with the endonuclease inhibitor"/>
 <result pre="of oseltamivir treatment on the incidence and course of acute" exact="otitis media" post="in children with influenza.Int J Pediatr Otorhinolaryngol. 2010;74:684â€&quot;688.20363510 34.HaydenFGde"/>
 <result pre="in children with influenza.Int J Pediatr Otorhinolaryngol. 2010;74:684â€&quot;688.20363510 34.HaydenFGde JongMDEmerging" exact="influenza" post="antiviral resistance threats.J Infect Dis. 2011;203:6â€&quot;10.21148489 35.LinaBBoucherCOsterhausAet al.Five years"/>
 <result pre="monitoring for the emergence of oseltamivir resistance in patients with" exact="influenza" post="A infections in the influenza resistance information study.Influenza Other"/>
 <result pre="oseltamivir resistance in patients with influenza A infections in the" exact="influenza" post="resistance information study.Influenza Other Respir Viruses. 2018;12:267â€&quot;278.29265727"/>
</results>
